The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
Open accessAbstract
Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined. Methods: Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years). Cox models were used to assess the independent prognostic value of Lp(a) and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration. Results: The median (interquartile range) baseline Lp(a) concentration was 37 (13–165) nmol/L. In the placebo arm, patients with baseline Lp(a) in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95% CI, 1.01–1.48) independent of low-density lipoprotein cholesterol. At 48 weeks, evolocumab significantly reduced Lp(a) by a median (interquartile range) of 26.9% (6.2%–46.7%). The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking evolocumab was moderately positively correlated ( r =0.37; 95% CI, 0.36–0.39; P <0.001). Evolocumab reduced the risk of coronary heart disease death, myocardial infarction, or urgent revascularization by 23% (hazard ratio, 0.77; 95% CI, 0.67–0.88) in patients with a baseline Lp(a) >median, and by 7% (hazard ratio, 0.93; 95% CI, 0.80–1.08; P interaction=0.07) in those ≤median. Coupled with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years were 2.49% and 40 versus 0.95% and 105, respectively. Conclusions: Higher levels of Lp(a) are associated with an increased risk of cardiovascular events in patients with established cardiovascular disease irrespective of low-density lipoprotein cholesterol. Evolocumab significantly reduced Lp(a) levels, and patients with higher baseline Lp(a) levels experienced greater absolute reductions in Lp(a) and tended to derive greater coronary benefit from PCSK9 inhibition. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, greater MACE reductions were seen among patients whose highly elevated Lp(a) levels were reduced by evolocumab [193].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [193]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding has also been supported by randomised control trials which shown that PCSK9 inhibition with evolocumab provides modest (16%) reduction in Lp(a) levels in patients with high Lp(a) levels43.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The net effect is a muted class response, with Lp(a) typically lowering around 20 to 30%, well below the reductions seen with LDL C and ApoB [25].”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although recent studies with PCSK9 inhibitors were not designed to target patients with high Lp(a) concentrations, they nevertheless revealed that patients with higher baseline Lp(a) concentration experienced greater absolute reductions in Lp(a) and tended to derive greater clinical benefit from PCSK9 inhibition [27,28].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“evolocumab in the FOURIER trial reduced Lp(a) by a median of 26.9% at 48 weeks[2,25], and alirocumab in ODYSSEY OUTCOMES showed a median relative reduction of −23% by 4 months[3,26].”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [25]
In the citing paper
“In contrast, Mendelian randomization studies have consistently demonstrated that lifelong exposure to higher Lp(a) levels is strongly and causally associated with an increased risk of ASCVD [74,75].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationBurgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1470 · Cited by 689
Self-citationTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H. E., Blom, D. J., Eriksson, M., Dent, R. E., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 359
Self-citation
Cited by
Sorted by citations
Items 701–800 of 982
The Importance of Apo B and Lipoprotein Little a [Lp(a)]
Alpert, J. S., & Stone, N. J. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.02.025 · Cited by 2
Rivera, F. B., Cha, S. W., Magalong, J. V., Tang, V. A. S., Enriquez, M. G., Gulati, M., Enkhmaa, B., Pagidipati, N. J., & Shah, N. P. (2024) · medRxiv · doi:10.1101/2024.07.10.24310245 · Cited by 2
Wu, A.-X., Wang, X.-J., Zhao, C., Hu, J.-Q., Li, J.-W., Xu, Y., Li, Y., & Liu, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108178 · Cited by 1
Omran, L. M., Alourfi, Z., & Barakat, Y. A. (2022) · Arab Board Medical Journal · doi:10.4103/abmj.abmj_2_22 · Cited by 1
Cesaro, A., Scherillo, G., Michele, G. D., Acerbo, V., Signore, G., Panico, D., Porcelli, G., Scialla, F., Raucci, G., Rotolo, F. P., et al. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.35 · Cited by 1
Should we already deal with lipoprotein(a) in clinical practice?
Vantová, Z., & Mayer, O. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.032 · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Williams, K. L., Augustine, M., Sujakhu, E., Magadia, J., Crawford, L., Knott, A., Hamilton, S., & Obiaka, U. (2024) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2024.101775 · Cited by 1
Cardozo, F. A. M., Bichuette, L. D., & Caramelli, B. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2463348 · Cited by 1
“Higher Lp(a) levels can be found in approximately 20% of the population and are most genetic related [30,31].”
Lipoprotein(a) levels and cardiovascular mortality risk in Chinese patients undergoing hemodialysis
Liang, Q., Zhang, G., Jiang, L., Li, B., & Song, K. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04459-5 · Cited by 1
“In the FOURIER trial, a randomized study involving 25,096 patients, evolocumab was found to significantly reduced Lp(a) levels by approximately 27% and appeared to provide greater coronary benefit through PCSK9 inhibition [36].”
Clinical Update on the Intersection of Lipoprotein(a) and Calcific Valve Disease
Ashley, S. C., Kachhy, E., Brown, K. A., Prescott, M. E., Kelsey, M. D., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00765-w · Cited by 1
Lipoprotein(a)—Investigating Sex-Based Differences Across the Lifespan in Men and Women
Driesenga, S., Schikowski, E. M., Koczo, A., Hauspurg, A. K., Countouris, M. E., & Saeed, A. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00768-7 · Cited by 1
“Two large, randomized control trials, ODYSSEY OUT-COMES [55] and FOURIER [56], have evaluated the impact of PCSK-9 inhibitors on LDL-C and Lp(a).”
Mitigating atherosclerosis: Integrating vaccines with gene targets
Haraj, A., Bakhshandeh, M., Shokri, N., Rad, P. S., Alyan, A., Chegini, Z., Nazari, M. A., Taji, S. P. S., & Najafi, M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100588 · Cited by 1
Sohn, W. Y., Tan, K. C. B., Shah, T., Du, Y., Wang, J., Zhang, S., Flach, S. D., & Ward, J. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.07.021 · Cited by 1
Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.25-94 · Cited by 2
Jordan, A. J., Balmforth, C., Craig, N. J., Dhaun, N., Baker, A. H., Dweck, M. R., & Newby, D. E. (2025) · Heart · doi:10.1136/heartjnl-2024-325280 · Cited by 2
Asbaita, M., Albaree, M., Mokhtar, J., Baroodi, N., Badla, B. A., Abdalbari, K., Najjar, A. A., Avci, M., & El‐Tamimi, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133996 · Cited by 2
Uddin, M., Shah, A., Hemida, M. F., Afridi, M. J., Bacha, Z., Iftikhar, H., Khan, S., Saif, H., Jamal, A., Syed, A., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.012 · Cited by 1
Zhang, Y., Tian, Q., Wang, H. T., Yu, C. Y., Wang, L., Zhu, Y., Shao, L., & Mo, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1644135 · Cited by 1
Sanchez, C. A. V., Lopes, R. A., & Shapiro, M. D. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01128-9 · Cited by 2
“Although therapies such as PCSK9 inhibitors can modestly reduce Lp(a) levels, typically by 20–25%, the extent to which this reduction translates into improved cardiovascular outcomes specifically attributable to Lp(a) remains uncertain [ 33 ].”
Razavi, A. C., Sokolsky, M., Belanger, M., Blazoski, C. M., Spitz, J. A., Sperling, L. S., Blumenthal, R. S., & Whelton, S. P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101417 · Cited by 1
“In the FOURIER trial, the number needed to treat with evolo-cumab to prevent one ASCVD event over three years was 40 for individuals with Lp(a) greater than the median value of 37 nmol/L and 105 for individuals with Lp(a) less than the median values of 37 nmol/L [71].”
A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques
Fukase, T., & Dohi, T. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00104-x · Cited by 2
“The FOURIER trial revealed that PCSK9 inhibitors signi fi cantly reduced Lp(a) levels (median reduction 27%), and patients with higher baseline Lp(a) levels experienced greater absolute reductions and appeared to derive more pronounced coronary bene fi ts 94 .”
Sweilam, S. H., Al-Kuraishy, H. M., Mustafa, A. M., Hassan, S. M., Alsharari, R., & Batiha, G. E. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104925 · Cited by 1
Popiołek-Kalisz, J., & Sabouret, P. F. (2026) · Advances in Medical Sciences · doi:10.1016/j.advms.2026.02.006 · Cited by 1
Courtney, W., Walker, J. A., Dorai-Raj, A., Arnous, S., O’Connor, C. T., Playford, D. A., Ihdayhid, A. R., Schultz, C. J., Hillis, G. S., & Kiernan, T. J. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2652411 · Cited by 1
Gouda, P., Secemsky, E. A., Hess, C. N., Arya, S., Fokorede, F., Mehran, R., Bonaca, M. P., Patel, M. R., & Jones, W. S. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107446 · Cited by 1
Yamada, T., Tada, H., Ogura, M., Funabashi, S., Yoshida, H., Hiraishi, C., Ebihara, T., Hadano, T., Masaki, T., Takeji, Y., et al. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66185 · Cited by 2
“Third, although PCSK9 inhibitor use may have influenced the Lp(a) levels, data on these factors were not available from some participating institutions and, thus, could not be included in the analysis 9, 26, 27) .”
Almahmeed, W. A., Sabbour, H. M., Shantouf, R. S., Aljaberi, A. K., Tamimi, H. E., Lootah, F. B., Sayed, N. A., Ali, J. A., Akbar, M. A. J., Shehab, A., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100569 · Cited by 1
“For example, The FOURIER trial demonstrated that evolocumab lowered Lp(a) levels by a median of 26.9% and was associated with a reduction in CV events [120].”
InfluentialAtallah, Nasrallah, N., Harb, T., Valenta, I., Schindler, T. H., Wallace, A. S., Tsimikas, S., Gerstenblith, G., & Leucker, T. M. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00821-7 · Cited by 1
“These findings complement post-hoc analyses from large PCSK9 inhibitor trials showing that greater on-treatment Lp(a) reductions correspond to fewer cardiovascular events, and provide a biological substrate, localized myocardial inflammation, through which this relationship may operate 27,28 .”
Old and New Lines of Therapy Targeting Lipoprotein(a)
Anchouche, K., Koran, N., & Thanassoulis, G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01419-x · Cited by 2
“…the reduction in MACE with evolocumab was significantly greater among participants with baseline Lp(a) levels above the cohort median (HR 0.77; 95% CI 0.67–0.88) as compared with those below the median (HR 0.93; 95% CI 0.80–1.08), suggesting enhanced benefit in individuals with elevated Lp(a) [10].”
InfluentialZayed, J. A., Al‐Awamleh, N. A., Hamad, M., Hdaib, M. I. M., & Ayesh, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70944 · Cited by 2
Lipoprotein(a): a therapeutic target in waiting? Evidently, evidence-based
Zeng, R., & Li, J.-J. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.06.035 · Cited by 1
Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target
Epelde, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1908850 · Cited by 1
“PCSK9 inhibitors reduce Lp(a) by approximately 20% − 30% in many patients and reduce ASCVD events, but they were developed primarily for LDL-C lowering and have not been tested specifically for CAVS prevention or progression (71).”
Lipoprotein(a): from the complex metabolism to the optimal lowering drug
Barbagallo, F. D. G., Berteotti, M., Bosco, G., Cosco, L., Pino, A. D., Alfano, F., Piro, S., Scicali, R., Masana, L., & Marcucci, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04492-x · Cited by 1
Sarraju, A., Du, X., Zhou, L., Laffin, L. J., Wolski, K., Gu, Y., Liu, Z., Zhang, Q., Cui, K., Yong, X., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01484-4 · Cited by 2
Lipoprotein(a) management simplified: The National Lipid Association lipid simplified series
Koschinsky, M. L., & Ballantyne, C. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.013 · Cited by 1
Current and Emerging Therapies for Atherosclerosis
Nelson, A. J., & Nicholls, S. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_4 · Cited by 2
Genetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 1
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_14 · Cited by 1
Lan, N. S. R., Dwivedi, G., & Bell, D. A. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.03.280 · Cited by 1
Katzmann, J. L., Custodis, F., Schirmer, S. H., & Laufs, U. (2022) · Herz · doi:10.1007/s00059-022-05112-y · Cited by 1
Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years
Seo, Y.-H., & Shin, H. (2022) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2022.54.2.95 · Cited by 1
Muhammad, A. (2022) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410271 · Cited by 1
“It has been observed that PCKS9 inhibitor evolocumab can also reduce LP(a) plasma levels by 25%, but this is not enough to eradicate the risk of AMI [ 30].”
Background王, 有. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132186 · Cited by 1
Classic endocrine disorders: implications for cardiovascular disease
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00014-0 · Cited by 1
Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis
Zhao, L., Liu, Y., Cao, Z., Wang, J., & Huo, X. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i5.12707 · Cited by 1
PCSK9-hemmere på blå resept for hvem?
Semb, A. G., Vesterbekkmo, E. K., Retterstøl, K., Atar, D., Solberg, E. E., Schirmer, H., Løchen, M., Kask, A., Grimsmo, J., Ingul, C. B., et al. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0191 · Cited by 1
Lipoprotein(a): Metabolism, Pathophysiology, and Impact on Diabetes Mellitus
Kostner, K., & Kostner, G. M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_10 · Cited by 1
Jin, Z., He, T., Peng, L. J., Wu, X., Fan, D., Chen, M., Fan, Y., Guo, Y., Lu, Z., & Wang, H. (2023) · Current Medical Science · doi:10.1007/s11596-023-2791-9 · Cited by 1
“In the Further cardiovascular OUtcomes Research with PCSK9 Inhibition subjects with Elevated Risk (FOURIER) study, the median (95% CI) for the Lp(a) levels of the 25 096 ASCVD patients was 37 (13–165) nmol/L, which is equal to approximately 14.5 (5–63) mg/dL [19] .”
InfluentialRecent updates on therapeutic targeting of lipoprotein(a) with RNA interference
Sekhar, A., Kuttan, A., & Lange, R. A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001144 · Cited by 1
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.04.001 · Cited by 1
RetractedShaMa, A., Xu, C., Huang, Y., Ma, C., Hu, J., Li, Z., & Zeng, C. (2024) · Herz · doi:10.1007/s00059-024-05247-0 · Cited by 1
Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation
Masson, W. M., Waisman, G. D., Corral, P., Cobo, A. L., Huerin, M. S., Barbagelata, L., & Siniawski, D. A. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00649-x · Cited by 1
Serum Lipoprotein(a) and Angiographic Severity of Coronary Artery Disease in Asian Indians
Sandhu, A. S., & Ahmed, I. (2024) · Research in Cardiovascular Medicine · doi:10.4103/rcm.rcm_19_24 · Cited by 1
The implications of measuring lipoprotein(a) in clinical practice
Barbir, M., Pottle, A., & Bornstein, S. R. (2024) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2024.40 · Cited by 1
“A meta-analysis showed that PCSK9 inhibitors lowered Lp(a) levels by 26% in addition to improving cardiac outcomes 15 .”
BackgroundГиполипидемическая терапия в особых ситуациях
Арутюнов, Г. П., Владиславович, Е. М., Alieva, A. S., Иосифович, Ш. И., Orlova, Y. A., Koziolova, N. A., Тарловская, Е. И., Григорьева, Н. Ю., & Chesnikova, A. I. (2024) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2024.03.0008 · Cited by 1
Inhibiteurs PCSK9 en pratique clinique : données et interrogations
Vergès, B. L., Dubois, C., & Legris, P. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.010 · Cited by 1
Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease
Mahajan, K., & Chandra, K. S. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620943020 · Cited by 1
Zavrtanik, M., Likozar, A. R., & Šebeštjen, M. (2021) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3057
Martinez, L. O., Perret, B., & Genoux, A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000771 · Cited by 1
Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment
Sykes, A. V., Patel, N., Lee, D. H., & Taub, P. R. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01775-5 · Cited by 2
Approche de la stratification du risque de maladies cardiovasculaires athéroscléreuses
Esau, D., & Abramson, B. L. (2022) · Canadian Family Physician · doi:10.46747/cfp.6809e256
Kulkarni, V., Shetty, S., Bhandary, R. R., Chakraborty, A., & Subramanya, K. (2022) · Biomedicine · doi:10.51248/.v42i6.1999 · Cited by 1
Therapy of Elevated Lipoprotein(a)
Ibrahim, S., & Stroes, E. S. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_21 · Cited by 2
Self-citationAlirocumab in Polyvascular Atherosclerotic Disease
Alkhalil, M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.072 · Cited by 1
Shapiro, M. D., & Fazio, S. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.04.010 · Cited by 1
Self-citationQi, Z., Sun, A., & Ge, J. (2020) · Circulation · doi:10.1161/circulationaha.120.049350 · Cited by 1
Lipoprotein(a): Solving the Puzzle, Deciphering the Riddle, Unraveling the Enigma
Thanassoulis, G. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.018 · Cited by 1
Goonewardena, S. N., Jurga, T., Lloyd‐Jones, D. M., Damodaran, D., Thyagarajan, B., Jacobs, D. R., Shore, S., Brandt, E. J., Clish, C. B., Tanrıverdi, K., et al. (2024) · medRxiv · doi:10.1101/2024.05.12.24307240 · Cited by 1
Rehman, M. B., & Tudrej, B. V. (2024) · Preprints.org · doi:10.20944/preprints202405.1317.v1
Olpasiran Pharmacodynamic Study
Spitz, J. A., & Agarwala, A. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.063 · Cited by 1
Are you implementation ready? An alternative patient and healthcare system-centered model for pharma
Olson, M., & Freitas, R. L. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0094 · Cited by 1
“Furthermore, although some approved therapies have shown to lower Lp(a) levels [12 , 13] , that is not their labeled indication.”
Lipoprotein(a) After HORIZON: Causal Culprit, Risk Marker, or Unfulfilled Therapeutic Promise?
Borovac, J. A., & Belančić, A. (2026) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484261492865 · Cited by 1
Pintó, X., & Sarasa, I. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.05.005
Use of Inflammatory Biomarkers to Predict the Clinical Benefit of Ezetimibe
Schwartzbard, A. Z., & Ahmad, A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.037
Sánchez Vega, J. D., & Zamorano Gómez, J. L. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.27
PCSK9 Inhibition—A Tale of 2 Potential Treatment Opportunities—Reply
Bergmark, B. A., & Sabatine, M. S. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.5613
Self-citationMurín, J., Bulas, J., & Wawruch, M. (2020) · Cardiology letters · doi:10.4149/cardiol_2020_4_7
Lipoprotein (a): Principles from Bench to Bedside
Koschinsky, M. L., & Boffa, M. B. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_19
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
McNeal, C. J., & Peterson, A. L. H. (2020)
Impact of Dyslipidemia on Ischemic Stroke
Kim, Y., & Kim, E. G. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_3
González, A. V., Domínguez-Mayoral, A., Chacón, M. D. L. R. D. T., & Castilla‐Guerra, L. (2021) · Revista de Neurología · doi:10.33588/rn.7401.2021188
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_9-1
Nakamura, A., Sato, K., Kondo, M., & Endo, H. (2022) · SAGE Open Medical Case Reports · doi:10.1177/2050313x221074464
Lp (a): An Independent Predictive Marker In DiseasesPreprint
Wu, M., Liu, W., & Xiang, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1290162/v1
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Santangelo, G., Bernardi, N., Faggiano, A., Bonelli, A., Toriello, F., Faggiano, P. M., & Carugo, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102902
Coronary Artery Calcium-Based Approach to Lipid Management
Kole, A., & Joshi, P. H. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00704-z
Xu, Z. Y., Zhang, L. L., Wang, S. H., & Wang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2064069/v1
Zhu, H., & Zheng, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-2247410/v1
Commentary to "How to Treat Peripheral Arteriovenous Malformations"
Candela, E. (2023) · Angiología · doi:10.20960/angiologia.00486
Research Progress of Lipoprotein a in Cardiovascular Disease
谭, 兴. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131042
Toth, P. P. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.007
Relationship between Lipoprotein a and Coronary Slow Flow Phenomenon
高, 亮. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132286
Role of Proprotein Convertase Subtilisin Kexin Type 9 in Lipoprotein(a) Metabolism
Gallo, A., Chemello, K., Techer, R., Jaafar, A. K., & Lambert, G. C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_6
Lipoprotein Apheresis for Reduction of Lipoprotein(a)
Julius, U., & Tselmin, S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_23
Kostner, G. M., & Kostner, K. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_25
Measurement of Lipoprotein(a) in the Clinical Laboratory
SULLIVAN, D. R., Woolnough, C. A., Perera, N., Ramanathan, J., & Badrick, T. C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_18
Metadata
- Authors
- O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., Ezhov, M. V., Jukema, J. W., Jensen, H. K., Tokgözoğlu, S. L., Mach, F., Huber, K., Sever, P. S., Keech, A. C., Pedersen, T. R., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Germany (I.G.-B.).
- Amgen, Thousand Oaks, CA (A.L.P., S.M.W.).
- Amgen (United States) (US)
- Charles University (CZ)
- National Cardiology Research Center, Moscow, Russia (M.V.E.).
- Leiden University Medical Center (NL)
- Aarhus University (DK)
- Cardiovascular Division, Hacettepe University, Ankara, Turkey (S.L.T.).
- University of Geneva (CH)
- Sigmund Freud Privatuniversität Wien (AT)
- Imperial College London (GB)
- The University of Sydney (AU)
- Oslo University Hospital (NO)
- ORCID
- Venue
- Circulation
- Published
- 2019-03-19
- Volume
- 139
- Issue
- 12
- Pages
- 1483-1492
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2940327706
- Cited by
- 984
- References
- 33
- Citations by year
- 2026: 133 · 2025: 153 · 2024: 157 · 2023: 134 · 2022: 120 · 2021: 100 · 2020: 122 · 2019: 64
- FWCI
- 97.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Abbott Laboratories
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Brigham and Women's Hospital
- Gilead Sciences
- Alnylam Pharmaceuticals
- Univerzita Karlova v Praze
- Aarhus Universitet
- Aarhus Universitetshospital
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Amarin Corporation
- Medicines Company
- Mylan
- MyoKardia
- Imperial College London
- Universiteit Leiden
- Daiichi-Sankyo
- Eisai
- Novo Nordisk
- Leids Universitair Medisch Centrum
- Universitetet i Oslo
- Hacettepe Üniversitesi
- Université de Genève
- Universität zu Köln
- Novo Nordisk Fonden (NNF18OC0031258)
- Servier
- Esperion Therapeutics
- Medical Research Council
- National Health and Medical Research Council
- Sydney Medical School
- Janssen Research and Development
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- lipoprotein(a), PCSK9 inhibitors, evolocumab, cardiovascular risk, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, urgent revascularization, LDL cholesterol, prognostic factors, FOURIER trial, LDL cholesterol lowering
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Aged, 80 and over, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Placebo Effect, Proportional Hazards Models, Treatment Outcome, Lipoprotein(a), Atherosclerosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
